The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Efficacy and prognostic indicators of IsaPd in Dara-refractory multiple myeloma: A real-world study
|
Key trials such as ICARIA-MM and IKEMA have demonstrated the efficacy of isatuximab in combination with pomalidomide and dexamethasone (IsaPd) or carfilzomib and dexamethasone (IsaKd). However, there are limited data on the efficacy of isatuximab in the setting of Dara-refractory MM. An analysis from a real-world study evaluating the efficacy in patients with Dara-refractory MM was published in Hematological Oncology by Martino et al.1 A total of 51 patients with RRMM treated with ≥1 cycle of IsaPd between January 2021 and June 2024 across 51 centers in Italy were included. Clinical outcomes included ORR, 12-month PFS, and 12-month OS. |
| Key learnings |
| Patients treated with IsaPd had an ORR of 56.9%, with 12-month OS and PFS rates of 63.4% and 30.6%, respectively. |
| Patients with a Hb level <11.8 g/L vs ≥11.8 g/L at baseline were 3.5-times more likely to experience disease progression (HR, 3.5; 95% CI, 1.5–8.4), with a median PFS of 4.6 months vs 22.0 months, respectively (p = 0.038). |
| Patients with a Hb level <11.0 g/L vs ≥11.0 g/L at baseline had a 10-fold increased risk of mortality (HR, 10.7; 95% CI 3.0–37.9; p < 0.001). |
| Patients with high-risk cytogenetic abnormalities had an approximately 10-fold increased risk of disease progression (HR, 9.6; 95% CI, 2.4–38.3; p < 0.0001). |
| This real-world study shows the efficacy of IsaPd and the significance of Hb level for predicting outcomes in patients with Dara-refractory RRMM. Use of immune-based therapies and biomarkers may be pivotal in refining treatment strategies and improving outcomes in this patient population. |
Abbreviations: CI, confidence interval; Dara, daratumumab; Hb, hemoglobin; HR, hazard ratio; Isa, isatuximab; IsaKd, isatuximab-carfilzomib-dexamethasone; IsaPd, isatuximab-pomalidomide-dexamethasone; MM, multiple myeloma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RRMM, relapsed/refractory multiple myeloma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
